GlassScriptPhysician profile
Joseph Momen
NPI 1114937653
$1,458.10
in general payments reported to CMS, 2019-2025
15 companies · $274 in 2025
The $274 reported for 2025 was more than what 82% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $180 · 2020: $136 · 2021: $134 · 2022: $111 · 2023: $461 · 2024: $162 · 2025: $274.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $898.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $897.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $303.88 | 2019-2024 | Jornay Pm |
| Pfizer INC. | $175.61 | 2019-2024 | |
| Tris Pharma INC | $174.33 | 2019-2025 | Dyanavel Xr, Quillivant |
| Collegium Pharmaceutical, INC. | $160.79 | 2025 | Jornay Pm |
| Glaxosmithkline, LLC. | $147.20 | 2019-2025 | Bexsero, Pediarix |
| Corium, LLC | $140.85 | 2023-2024 | Azstarys |
| Genzyme Corporation | $100.09 | 2021 | |
| Merck Sharp & Dohme LLC | $81.37 | 2019-2024 | Vaxneuvance, Gardasil 9, Proquad |
| Takeda Pharmaceuticals U.S.A., INC. | $41.03 | 2020-2021 | |
| Ars Pharmaceuticals Operations, INC. | $37.75 | 2025 | Neffy |
| Sanofi Pasteur INC. | $23.78 | 2025 | |
| Seqirus USA INC | $18.95 | 2025 | Flucelvax |
| Organon LLC | $18.33 | 2023 | Nexplanon |
| Adlon Therapeutics L.P. | $17.23 | 2020 | |
| Genentech USA, INC. | $16.91 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Momen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.